THERAVANCE BIOPHARMA INC
TBPHNASDAQTrading Snapshot
- Day Range
- $16.86 – $17.06
- 52-Week Range
- $11.20 – $21.03
- Volume
- $2.42B
- Avg Volume
- $2.62B
- Shares Outstanding
- 51.8M
- Next Earnings
- Sep 16, 2026
Fundamentals Snapshot
- Annual Revenue
- $107M
- Last Q Revenue
- $21M
- P/E Ratio
- 7.7
- P/S Ratio
- 8.0x
- EPS (TTM)
- $2.20
- Dividend Yield
- —
Why Investors Own TBPH
- ✓High-growth profile — revenue up +29.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 40% gross margin and 27% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About THERAVANCE BIOPHARMA INC
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.